Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Abemaciclib and Letrozole to Treat Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 53
- Registration Number
- NCT04393285
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸University of Miami - Sylvester Cancer Center, Miami, Florida, United States
Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 30
- Registration Number
- NCT04364581
- Locations
- 🇪🇬
Mansoura University Hospital, Mansoura, Dakahlia, Egypt
Cost Effectiveness Analysis for Induction of Ovulation in the Polycystic Ovary Syndrome by Letrozole Versus Clomiphene Citrate
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 212
- Registration Number
- NCT04361175
Hormone Secretion in Transgender Males
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 40
- Registration Number
- NCT04321551
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT04316169
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 120
- Registration Number
- NCT04308343
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 69
- Registration Number
- NCT04300790
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Hospital Universitario de Leon, León, Spain
🇪🇸Hospital Beata María Ana, Madrid, Spain
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 161
- Registration Number
- NCT04294225
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 200
- Registration Number
- NCT04293393
- Locations
- 🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 565
- Registration Number
- NCT04289805
- Locations
- 🇧🇪
CUB-Hôpital Erasme, Brussel, Belgium
🇧🇪CHC-Saint Vincent, Liège, Belgium
🇧🇪CHIREC- Hospital Delta, Brussel, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.